Method for the determination of gonadotropins

• US 4,123,510 A
• Filed: 06/14/1977
• Issued: 10/31/1978
• Est. Priority Date: 04/11/1977
• Status: Expired due to Term

• Current Assignee: American Home Products Corporation (Pfizer Inc.)
• Original Assignee: American Home Products Corporation (Pfizer Inc.)
• Inventors: Givner, Morris L., Banik, Upendra K.
• Primary Examiner(s): Fagelson, Anna P.
• Application Number:
  US05/806,569
• Time in Patent Office: 504 Days
• Field of Search: 210/DIG. 23, 210/23 F, 210/22 R, 424/8, 424/12, 424/99, 424/100, 424/101, 424/108, 23/230 B, 23/259
• US Class Current: 436/520
• CPC Class Codes: B01D 61/145 Ultrafiltration
• CPC Class Codes: B01D 63/00 Apparatus in general for separation processes using semi-permeable membranes
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
• CPC Class Codes: G01N 33/76 Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
• CPC Class Codes: Y10S 436/811 Test for named disease, body condition or organ function
• CPC Class Codes: Y10S 436/814 Pregnancy
• CPC Class Codes: Y10S 436/817 Steroids or hormones
• CPC Class Codes: Y10S 436/818 Human chorionic gonadotropin
• CPC Class Codes: Y10S 436/825 Pretreatment for removal of interfering factors from sample

Abstract

A simple, sensitive, reliable and safe method for determining the concentration of pituitary gonadotropins is disclosed. The method involves concentration by ultrafiltration of a sample of body fluid, e.g. urine or serum from a subject, followed by determining the presence of the gonadotropin in the concentrated sample.

Claims

1. A method suitable for detection of luteinizing hormone in urine at a concentration as low as about 25 m.I.U./ml of urine and capable of detecting ovulation in a cycling woman, which comprises:

(a) clarifying a sample of the urine to be tested;

(b) contacting the urine sample before, during or after clarification with 0.1 to 5% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemomycin so that adsorption of luteinizing hormone from the sample onto the membrane is substantially reduced;

(c) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000, whereby luteinizing hormone is retained in the sample;

(d) continuing the ultrafiltration until the retentate sample is concentrated to one-tenth to one-five hundredth its original volume;

(e) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and

(f) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of luteinizing hormone in the retentate sample.

2. The method of claim 1 in which the luteinizing hormone is detected by a luteinizing hormone antiserum or a human chorionic gonadotropin antiserum which cross reacts with luteinizing hormone.

3. A method for detecting follicle stimulating hormone or human menopausal gonadotropin in urine at a concentration of 15 or more m.I.U./ml of urine, which comprises:

(a) clarifying a sample of the urine to be tested;

(b) contacting the urine sample before, during or after clarification with 0.1 to 5% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemomycin so that adsorption of follicle-stimulating hormone or human menopausal gonadotropin from the sample onto the membrane is substantially reduced;

(c) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000, whereby follicle-stimulating hormone or human menopausal gonadotropin is retained in the sample;

(d) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume;

(e) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and

(f) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of follicle-stimulating hormone or human menopausal gonadotropin.

4. A test method suitable for detection of pituitary gonadotropins in urine at a concentration as low as about 15 m.I.U./ml of urine which comprises:

(a) clarifying a sample of the urine to be tested;

(b) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane, said membrane having been prewashed with 0.1 to 5% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglogin, fibrinogen, human hemoglobin, and keyhold limpet hemocyanin so that adsorption of the gonadotropin from the sample onto the membrane is substantially reduced, and said membrane having a molecular weight cut-off from about 5,000 to about 50,000 whereby the gonadotropin is retained in the sample;

(c) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume;

(d) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and

(e) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of the gonadotropin in the retentate sample.

5. The method of claim 4 wherein said ultrafiltration membrane is of the anisotropic type and in which the membrane has a molecular cut-off from about 10,000 to about 35,000.

6. The method of claim 4, wherein said ultrafiltration membrane is of the anisotropic type and the concentration of said solution of protein is from 0.1 to 1.0%.

7. The method of claim 4 wherein said clarifying step comprises filtration through a filter and which further comprises prewashing said filter with the aqueous solution of a protein.

8. A test method suitable for detection of pituitary gonadotropins in urine at a concentration as low as about 15 m.I.U./ml of urine which comprises:

(a) clarifying a sample of the urine to be tested;

(b) contacting the urine sample before or after clarification with a sufficient amount of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemocyanin to give a concentration of the protein in the urine of from 0.001 to 1.0% so that adsorption of the gonadotropin from the sample onto the membrane is substantially reduced;

(c) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000 whereby the gonadotropin is retained in the sample;

(d) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume;

(e) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and

(f) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of the gonadotropin in the retentate sample.

9. The method of claim 8 wherein said membrane is of the anisotropic type, said membrane being backed by a layer of absorbent capable of sorbing urine.

10. The method of claim 9 wherein the concentration of said protein in the urine is from 0.01 to 1.0%.

11. A test method suitable for detection of pituitary gonadotropins in urine at a concentration as low as about 15 m.I.U./ml of urine, which comprises:

(a) clarifying a sample of the urine to be tested through a filter, said filter having been pretreated with an 0.1 to 5.0% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemocyanin so that adsorption of the gonadotropin from the sample onto the membrane is substantially reduced;

(b) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000, whereby the gonadotropin is retained in the sample;

(c) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume;

(d) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and

(e) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of the gonadotropin in the retentate sample.

12. The method of claim 11 in which said membrane is of the anisotropic type having a molecular weight cut-off from about 10,000 to about 35,000 and wherein the concentration of said solution of protein is from 0.1 to 1.0%.